249 related articles for article (PubMed ID: 37377956)
1. CrossDome: an interactive R package to predict cross-reactivity risk using immunopeptidomics databases.
Fonseca AF; Antunes DA
Front Immunol; 2023; 14():1142573. PubMed ID: 37377956
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
Cameron BJ; Gerry AB; Dukes J; Harper JV; Kannan V; Bianchi FC; Grand F; Brewer JE; Gupta M; Plesa G; Bossi G; Vuidepot A; Powlesland AS; Legg A; Adams KJ; Bennett AD; Pumphrey NJ; Williams DD; Binder-Scholl G; Kulikovskaya I; Levine BL; Riley JL; Varela-Rohena A; Stadtmauer EA; Rapoport AP; Linette GP; June CH; Hassan NJ; Kalos M; Jakobsen BK
Sci Transl Med; 2013 Aug; 5(197):197ra103. PubMed ID: 23926201
[TBL] [Abstract][Full Text] [Related]
3. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.
Raman MC; Rizkallah PJ; Simmons R; Donnellan Z; Dukes J; Bossi G; Le Provost GS; Todorov P; Baston E; Hickman E; Mahon T; Hassan N; Vuidepot A; Sami M; Cole DK; Jakobsen BK
Sci Rep; 2016 Jan; 6():18851. PubMed ID: 26758806
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Studies of the Off-Target Reactivity of AFP
Cai L; Caraballo Galva LD; Peng Y; Luo X; Zhu W; Yao Y; Ji Y; He Y
Front Immunol; 2020; 11():607. PubMed ID: 32395117
[TBL] [Abstract][Full Text] [Related]
5. TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan AR; Chaipan C; Winkelbach K; Wimberger S; Jeong JS; Joshi B; Stein RB; Underwood D; Castle JC; van Dijk M; Seibert V
Front Immunol; 2019; 10():2501. PubMed ID: 31695703
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
Linette GP; Stadtmauer EA; Maus MV; Rapoport AP; Levine BL; Emery L; Litzky L; Bagg A; Carreno BM; Cimino PJ; Binder-Scholl GK; Smethurst DP; Gerry AB; Pumphrey NJ; Bennett AD; Brewer JE; Dukes J; Harper J; Tayton-Martin HK; Jakobsen BK; Hassan NJ; Kalos M; June CH
Blood; 2013 Aug; 122(6):863-71. PubMed ID: 23770775
[TBL] [Abstract][Full Text] [Related]
7. IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing.
Pan Y; Phillips JW; Zhang BD; Noguchi M; Kutschera E; McLaughlin J; Nesterenko PA; Mao Z; Bangayan NJ; Wang R; Tran W; Yang HT; Wang Y; Xu Y; Obusan MB; Cheng D; Lee AH; Kadash-Edmondson KE; Champhekar A; Puig-Saus C; Ribas A; Prins RM; Seet CS; Crooks GM; Witte ON; Xing Y
Proc Natl Acad Sci U S A; 2023 May; 120(21):e2221116120. PubMed ID: 37192158
[TBL] [Abstract][Full Text] [Related]
8. POPISK: T-cell reactivity prediction using support vector machines and string kernels.
Tung CW; Ziehm M; Kämper A; Kohlbacher O; Ho SY
BMC Bioinformatics; 2011 Nov; 12():446. PubMed ID: 22085524
[TBL] [Abstract][Full Text] [Related]
9. CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.
Baumgaertner P; Schmidt J; Costa-Nunes CM; Bordry N; Guillaume P; Luescher I; Speiser DE; Rufer N; Hebeisen M
Front Immunol; 2022; 13():973986. PubMed ID: 36032094
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
[TBL] [Abstract][Full Text] [Related]
11. Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition.
Schneidman-Duhovny D; Khuri N; Dong GQ; Winter MB; Shifrut E; Friedman N; Craik CS; Pratt KP; Paz P; Aswad F; Sali A
PLoS One; 2018; 13(11):e0206654. PubMed ID: 30399156
[TBL] [Abstract][Full Text] [Related]
12. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.
Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M
Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595
[TBL] [Abstract][Full Text] [Related]
13. Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy.
Antunes DA; Rigo MM; Freitas MV; Mendes MFA; Sinigaglia M; Lizée G; Kavraki LE; Selin LK; Cornberg M; Vieira GF
Front Immunol; 2017; 8():1210. PubMed ID: 29046675
[TBL] [Abstract][Full Text] [Related]
14. GPU-Accelerated Discovery of Pathogen-Derived Molecular Mimics of a T-Cell Insulin Epitope.
Whalley T; Dolton G; Brown PE; Wall A; Wooldridge L; van den Berg H; Fuller A; Hopkins JR; Crowther MD; Attaf M; Knight RR; Cole DK; Peakman M; Sewell AK; Szomolay B
Front Immunol; 2020; 11():296. PubMed ID: 32184781
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.
Soon CF; Zhang S; Suneetha PV; Antunes DA; Manns MP; Raha S; Schultze-Florey C; Prinz I; Wedemeyer H; Sällberg Chen M; Cornberg M
Front Immunol; 2019; 10():2076. PubMed ID: 31552033
[TBL] [Abstract][Full Text] [Related]
16. In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy.
Dhanik A; Kirshner JR; MacDonald D; Thurston G; Lin HC; Murphy AJ; Zhang W
BMC Bioinformatics; 2016 Jul; 17():286. PubMed ID: 27439771
[TBL] [Abstract][Full Text] [Related]
17. T-cell Receptors Engineered
Sharma P; Harris DT; Stone JD; Kranz DM
Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
[TBL] [Abstract][Full Text] [Related]
18. Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity.
Eakins RA; Chobrutskiy A; Teer JK; Patel DN; Hsiang M; Huda TI; Zaman S; Sexton WJ; Coppola D; Falasiri S; Blanck G; Chobrutskiy BI
Mol Immunol; 2022 Oct; 150():58-66. PubMed ID: 35987136
[TBL] [Abstract][Full Text] [Related]
19. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
20. Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer.
Audehm S; Glaser M; Pecoraro M; Bräunlein E; Mall S; Klar R; Effenberger M; Albers J; Bianchi HO; Peper J; Yusufi N; Busch DH; Stevanović S; Mann M; Antes I; Krackhardt AM
Front Immunol; 2019; 10():1485. PubMed ID: 31316521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
